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Abstract
Differentiation, distribution and immune regulation of human IL-22-producing T cells in infections remain unknown.
Here, we demonstrated in a nonhuman primate model that M. tuberculosis infection resulted in apparent increases in
numbers of T cells capable of producing IL-22 de novo without in vitro Ag stimulation, and drove distribution of these
c e l l sm o r ed r a m a t i c a l l yi nl u n g st h a ni nb l o o da n dl y m p h o i d tissues. Consistently, IL-22-producing T cells were
visualized in situ in lung tuberculosis (TB) granulomas by confocal microscopy and immunohistochemistry, indicating
that mature IL-22-producing T cells were present in TB granuloma. Surprisingly, phosphoantigen HMBPP activation of
Vc2Vd2 T cells down-regulated the capability of T cells to produce IL-22 de novo in lymphocytes from blood, lung/BAL
fluid, spleen and lymph node. Up-regulation of IFNc-producing Vc2Vd2 T effector cells after HMBPP stimulation
coincided with the down-regulated capacity of these T cells to produce IL-22 de novo. Importantly, anti-IFNc
neutralizing Ab treatment reversed the HMBPP-mediated down-regulation effect on IL-22-producing T cells, suggesting
that Vc2Vd2 T-cell-driven IFNc-networking function was the mechanism underlying the HMBPP-mediated down-
regulation of the capability of T cells to produce IL-22. These novel findings raise the possibility to ultimately investigate
the function of IL-22 producing T cells and to target Vc2Vd2 T cells for balancing potentially hyper-activating IL-22-
producing T cells in severe TB.
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Introduction
IL-22 is a member of IL-10 cytokine family and primarily
produced by Th17 T cells [1]. IL-22 signals though its
heterodimer receptor comprised of IL-22R1 and IL-10R2 [2],
with the IL-22 binding effect dictated by IL-22R1 that are
expressed mainly on skin and mucosal epithelial cells such as
digestive system, respiratory system and kidney but not on
immune cells [1,3,4]. Upon binding to its receptor, IL-22 exerts
its effect by activating STAT signal transduction pathways [2,4].
Accumulating evidence suggests that IL-22 can be either
pathogenic/inflammatory or protective depending upon envi-
ronmental and host conditions. IL-22 has the ability to induce
antimicrobial peptide b-defensin 2 and 3 or psoriasin in
keratinocytes [2,4,5], and up-regulate host defense genes such
as Lcn2 (encoding lipocalin-2) [6,7]. IL-22 can also induce
expression of acute phase reactants to protect against acute liver
inflammation [2,3,4]. On the other hand, IL-22 can induce
inflammatory effects. IL-22 is indeed a major inflammatory
mediator in dermal inflammation and acanthosis in mouse
models [8,9]. However, it is not clear how IL-22-producing T
cells involve or orchestrate host immune response. Since the
subset of murine T cells producing IL-22 also produce IL-17 [1],
knowledge about the IL-22-producing T cells is mainly derived
from studies of IL-17-producing Th17 cells in autoimmune and
inflammatory diseases. In fact, development, function and
immune regulation of human IL-22-producing T cells in
infections remain largely unknown.
Tuberculosis remains one of the leading causes of morbidity and
mortality due to infectious diseases, with 8 million new cases and
.2 million deaths reported word-wide each year [10,11].
Although human CD4 T cells have been shown to be important
for protection against adult form of pulmonary tuberculosis [12],
the role of IL-22-producing T cells in TB is not known. While IL-
17 and IL-23 were investigated in mouse TB model [10,13], we
have recently demonstrated that severe tuberculosis induces
unbalanced up-regulation of immune gene networks and over-
expression of IL-22 in nonhuman primates [14]. It has also been
reported that Th17 cells producing IL-22 and IL-17 can be
detected by in vitro antigen re-stimulation-based intracellular
cytokine staining (ICS) in BCG-vaccinated and M. tuberculosis-
infected humans [15]. However, differentiation kinetics, local/
systemic distribution, and immune regulation of human IL-22-
producing T cells during M. tuberculosis infection remain unknown.
Elucidation of these aspects may potentially device immune
regulatory strategy in which immune responses of IL-22-producing
PLoS Pathogens | www.plospathogens.org 1 February 2010 | Volume 6 | Issue 2 | e1000789T cells can be balanced to facilitate protective response but
minimize inflammatory consequence in tuberculosis.
Vc2Vd2 T cells exist only in primates and constitute 60–95% of
circulating human cd T cells [16,17]. Studies from us and others
suggest that Vc2Vd2 T cells play a role in mediating anti-
microbial immune responses [18,19,20,21,22,23]. Vc2Vd2 T cells
can be specifically activated by certain low m.w. foreign- and self-
nonpeptidic phosphorylated metabolites of isoprenoid biosynthesis
[e.g. (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP)
and isopentenyl pyrophosphate (IPP)] [24,25,26,27]. We have
shown that HMBPP produced by M. tuberculosis and other
microbes is associated with antigen presenting cell (APC)
membrane and recognized by Vc2Vd2 TCR [28]. We have also
demonstrated that HMBPP-specific Vc2Vd2 T cells can readily
migrate and accumulate in the pulmonary compartment during
M. tuberculosis infection, and that rapid recall expansion of these
cells is associated with immunity against fatal tuberculosis in
juvenile rhesus monkeys [21,29]. More recently, we reported that
HMBPP activation of Vc2Vd2 T cells can antagonize IL-2-
induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial
infection [30], suggesting that Vc2Vd2 T cells may play a
regulatory role as well in immune responses against tuberculosis.
Our findings in the macaque TB model system raise the possibility
to study cell-cell interaction and mutual regulation between
Vc2Vd2 T cells and IL-22-producing T cells during M. tuberculosis
infection.
In the current study, we first demonstrated differentiation
kinetics and local/systemic distribution of IL-22-producing T cells
during M. tuberculosis infection of macaques. We then provided the
first evidence indicating that effector function of IL-22-producing
T cells differentiated from M. tuberculosis infection was susceptible
to down-regulation by HMBPP activation of Vc2Vd2 T cells. We
also elucidated an immune mechanism underlying HMBPP/
Vc2Vd2 T-cell-mediated immune regulation of IL-22-producing
T cells.
Results
M. tuberculosis infection drove apparent increases in
numbers of T cells capable of producing IL-22 or IL-17 de
novo without in vitro Ag stimulation in the blood and
BAL fluid
We have recently demonstrated that primary tuberculosis can
induce a 220-fold up-regulation of IL-22 transcripts in macaques
[14]. Another group used in vitro antigen stimulation-based assays to
detect human T cells producing IL-22 protein in cross-sectional
time points of tuberculosis [15]. Our findings at gene-expression
levels suggest that T cells actively producing IL-22 de novo may be
detected directly without in vitro antigen re-stimulation during M.
tuberculosis infection of macaques. Thus, macaques were infected
with M. tuberculosis by bronchoscope-guided inoculation as previ-
ously described [31,32], and assessed for the development of IL-22
producing T cells using the modified ICS that skipped in vitro
antigen re-stimulation (see Method section). Interestingly, signifi-
cant increases in numbers of T cells actively producing IL-22 in
blood wereseen at week 4 after M. tuberculosis infection, and at weeks
6 and 8, such increases were more apparent and sustained in the
blood of the infected macaques (Fig. 1A). Similarly, significant
increases in numbers of IL-22 producing T cells were also detected
in bronchoalveolar lavage fluids (BALF) during the infection
(Fig. 1A). On note, these IL-22-producing T cells were similarly
detected in the medium alone or medium plus CD3/CD28 mAbs
(Fig. 1B,and data notshown). Most T cells actively producingIL-22
were CD4+ T cells (Fig. S1 and [3,15]). Since it has been reported
that majority IL-17 expressing T cells also co-express IL-22 [5], we
similarly measured IL-17-producing T cells as described above.
Surprisingly, although numbers of IL-17-producing T cells
increased significantly over time after the infection, the magnitude
of increase in IL-17-producing T cells was significantly lower than
that in IL-22-producing T cells at weeks 6–8 after the infection
(Fig. 1A). In fact, we found that most of IL-22 producing T cells
weredistinct fromIL-17producingT cells(Fig.1C),withveryfewT
cells co-expressing IL-22 and IL-17. This suggested that these IL-22
and IL-17 producing T cells may differentiate distinctly during M.
tuberculosis infection of macaques. Thus, these results demonstrated
that T cells capable of producing IL-22 or IL-17 de novo could be
detected without in vitro antigen re-stimulation, and that M.
tuberculosis infection drove significant increases in numbers of IL-
22-producing T cells in the blood and airway.
T cells actively producing IL-17 or IL-22 were
preferentially increased in the lung with severe
tuberculosis lesions, whereas IL-22-producing T cells
were similarly distributed in the blood and lymphoid
tissues
Distribution of IL-22-producing T cells in lymphoid and
nonlymphoid compartments during M. tuberculosis infection
remains largely unknown. It is not known either whether
tuberculosis lesions in lung infection sites can preferentially drive
expansion of T effectors cells actively producing IL-22 or IL-17.
To address these questions, we isolated lymphocytes from BAL
fluid, and right caudal lung lobe (infection site), spleen and
mesentery lymph nodes obtained from the M. tuberculosis-infected
macaques, and measured T cells actively producing IL-17 or IL-22
without in vitro antigen re-stimulation. All the macaques showed
severe TB lesions in the infection site ([31,32] and data not shown).
While blood and lymphoid tissues accommodated similar numbers
of T cells actively producing IL-22, lymphocytes in lungs and BAL
fluid contained significantly greater numbers of IL-22-producing T
Author Summary
TB remains one of the leading causes of morbidity and
mortality among infectious diseases worldwide. Protective
immunity against TB in humans remains poorly character-
ized, although the importance of CD4 T cells is well
described in HIV-related TB. Similarly, little is known about
the role of newly-defined T helper 17 (Th17) cells
producing pro-inflammatory cytokine IL-17 or IL-22 during
M. tuberculosis infection of humans. Understanding im-
mune response, kinetics, distribution and regulation of
Th17 cells will help to elucidate immune function of these
cells in TB, and to explore Th17-targeted immunother-
apeutics. We therefore employed the nonhuman primate
TB model to study Th17 cells and their interaction with
Vc2Vd2 T cells, a major human cd T-cell subset having
regulatory potential. We demonstrated that M. tuberculosis
infection drove induction and distribution of IL-22-
producing T cells in blood, airway, lung, lymph node and
spleen. IL-22-producing T cells were most frequent in
lungs, and involved in TB granuloma formation. We further
showed that activation of Vc2Vd2 T cells could remarkably
down-regulate IL-22-producing T cells in blood and tissue
lymphocytes, and that such a down-regulation was
mediated by an IFNc-associated cytokine network. Our
findings provide new information regarding kinetics,
distribution and immune regulation of IL-22-producing T
cells in TB.
Immunology of IL-22-Producing T cells in TB
PLoS Pathogens | www.plospathogens.org 2 February 2010 | Volume 6 | Issue 2 | e1000789Figure 1. M. tuberculosis infection resulted in apparent increases in numbers of T cells capable of producing IL-22 without in vitro Ag
re-stimulation, and drove distribution of these cells more dramatically in lungs than in blood and lymphoid tissues. (A) Graphic data
show percentage numbers of T cells capable of producing IL-22 or IL-17 de novo in the blood (left) and BAL fluid (right) during M. tuberculosis
infection. The cells were directly measured by ICS in the presence of CD28/CD49d but without in vitro Ag stimulation. This would allow direct
evaluation of regulatory effect by Vc2Vd2 T effector cells in the presence or absence of HMBPP. Data are mean percentage numbers in CD3 T cells
with error bars of SEM derived from nine cynomolgus macaques. Data were gated on CD3 although most IL-22 cells were CD4 T cells (Fig. S1). This
would allow direct comparisons with Vc2Vd2 T cells within CD3 T-cell population as shown in Figs. 3–5. CD3+ T cells producing IL-22 or IL-17 in this
and other figures included Vc2Vd2 T cells. The magnitude of increase in IL-22+ T cells in PBL (
#) at weeks 4, 6 and 8 and in BAL fluid at week 8 were
significantly greater than that in IL-17+ T cells (*) (P,0.005).
# or *, P,0.05, **, P,0.01,
### or ***, P,0.001. (B) Bar graphic data show that
appreciable numbers of IL-22-producing T cells directly measured in medium alone were comparable with those detected in medium plus CD28/
CD49d mAbs or in medium plus CD3/CD28 mAbs. Data were mean 6 SEM from PBMC obtained at necropsy (8 weeks after infection) from nine
cynomolgus macaques. Similar data were seen at weeks 4 and 6 after M. tuberculosis infection. Data were gated on lymphocytes. (C) Representative
flow-cytometry histograms of intracellular cytokine staining analysis show that IL-22- and IL-17-producing T cells appear to be two distinct cell
populations. The percentage numbers of IL-22 (bottom, right), IL-17 (top, left) producing T cells and IL-22/IL-17 co-expressing T cells (top, right)i n
CD3 T cells are marked in the individual histograms. Data are CD3 gated. Similar data were repeatedly seen from at least 15 monkeys in blood (n=21),
BAL fluid (n=21), lung (n=15), spleen (n=17), mesenteric lymph node (n=20). (D) Bar graphic data show percentage numbers of T cells capable of
producing IL-22 (left) and IL-17 (right) within CD3+ T cells in lymphocytes isolated from blood, BAL fluid, lungs, spleens and lymph nodes (LN) at 8
weeks after M. tuberculosis infection. Data are mean 6 SEM derived from up to 16 macaques’ lungs (n=15, rhesus), spleens (n=16, rhesus),
mesenteric lymph nodes (n=16, rhesus), blood (n=9, cynomolgus), and BAL fluid (n=9, cynomolgus). Data were measured by the ICS without
antigen re-stimulation in the presence of medium plus CD28/CD49d mAb. Similar numbers of these cells were detected by the ICS in the presence of
medium only (data not shown). Data were gated on CD3. *, P,0.05, **, P,0.01, ***, P,0.001. All rhesus macaques included for all the figures are
Chinese rhesus macaques.
doi:10.1371/journal.ppat.1000789.g001
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apparently detectable in lung lymphocytes, although numbers of
these cells were quite low in the blood, spleen and mesentery
lymph nodes (Fig. 1D). Overall, numbers of IL-22-producing T
cells were consistently higher than those of IL-17-producing T cells
in all anatomic compartments tested (Fig. 1D).
To confirm the presence of T cells actively producing IL-22 in
lung tissues, we performed in situ detection of IL-22-producing T
cells using confocal microscopy imaging [33] and immunohisto-
chemistry [31,32]. IL-22 protein could readily be detected in
CD3+ T cells in the lung tissue sections from the right middle and
caudal lobes of M. tuberculosis-infected monkeys but not from
healthy BCG-vaccinated monkeys (Fig. 2A). The mean percentage
numbers of CD3+IL-22+ T cells were up to 6% in CD3+ T cells
(Fig. 2B). Similarly, the immunohistochemistry studies showed that
a number of IL-22-producing T cells were distributed in lung TB
granuloma in the right caudal lobe from M. tuberculosis-infected
monkeys but not in the lungs from the BCG-vaccinated controls
(Fig. 2C), indicating that IL-22-producing T cells were present in
TB granuloma. Taken together, T cells actively producing IL-17
or IL-22 were preferentially expanded in the lung infection site
with tuberculosis lesions, whereas IL-22-producing T cells were
similarly distributed in the blood and lymphoid tissues.
Phosphoantigen HMBPP activation of Vc2Vd2 T cells
down-regulated the capability of T cells to actively
produce IL-22 but not IL-17 de novo in lymphocytes from
blood, lung/BAL fluid, spleen and lymph nodes
The immune regulatory factors regulating T cells actively
producing IL-22 during infections have not been studied. Because
Vc2Vd2 T cells recognize phosphoantigen HMBPP produced by
M. tuberculosis and other microbes, and contribute to adaptive
immune responses and immune regulation in mycobacterial
infections [21,30], we sought to determine whether phophoantigen
activation of Vc2Vd2 T cells can exert a potential impact on IL-
22-producing T cells. Our finding that IL-22-producing T cells
and Vc2Vd2 T cells are both distributed in lungs, blood and
lymphoid tissues (Fig. 3A, 4A, 5A and [31]) in M. tuberculosis
infection provides a useful setting in which to study the interaction
between these two T-cell subpopulations. Thus, lymphocytes
isolated from the blood, lung/BAL fluid, spleen and lymph nodes
of the infected macaques were stimulated for one hr with HMBPP,
and then assessed for a change in the capability of T cells to
produce IL-22 de novo in comparison with that of lymphocytes
without Ag stimulation. Interestingly, HMBPP activation of
Vc2Vd2 T cells consistently led to down-regulation of the
capability of T cells to produce IL-22 de novo in lymphocytes from
blood, lung/BAL fluid, spleen and mesenteric lymph nodes
(Fig. 3A, 3B). The percentage numbers of T cells actively
producing IL-22 were reduced 1.4–7.9 folds after HMBPP
stimulation, with mean reduced folds being 1.7160.20 in blood
(p=0.0166), 2.5660.55 in BAL fluid (p=0.0249), 2.4360.36 in
lung (p=0.0430), 2.9860.53 in spleen (p=0.0446), and
1.9060.08 in lymph nodes (p=0.0188) when compared to
corresponding cell numbers detected without HMBPP stimulation
(Fig. 3A, 3B and 3c). In contrast, HMBPP activation of Vc2Vd2T
cells had almost no impact on the capacity of T cells to produce
IL-17 from the blood, lung/BAL fluid, spleen and lymph node
(Fig. 3D). This result suggested that HMBPP activation of Vc2Vd2
T cells selectively down-regulated IL-22-producing T cells but not
IL-17-producing T cells. Overall, the HMBPP-mediated reduction
in de novo production of IL-22 by T cells was seen in lymphocytes
from all the compartments, but the down-regulation appeared
more dramatic in lymphocytes from lung/BAL fluid and spleen
(Fig. 3A, 3B). This might be due to the fact that greater numbers of
Vc2Vd2 T cells were present in these compartments in
tuberculosis [31]. Stimulation of lymphocytes using overlapping
ESAT6/Ag85 peptides did not lead to significant reduction in IL-
22-producing T cells (data not shown). These results therefore
demonstrated that HMBPP activation of Vc2Vd2 T cells down-
regulated the capability of T cells to actively produce IL-22 de novo
during M. tuberculosis infection.
Up-regulation of IFNc-producing Vc2Vd2 T effector cells
after HMBPP stimulation coincided with the down-
regulated capacity of T cells to produce IL-22 de novo
We then asked the question as to whether effector function of
Vc2Vd2 T cells after HMBPP stimulation contributed to the
down-regulated capability of T cells to actively produce IL-22 de
novo. Since IFNc is one of the major cytokines produced by
phosphoantigen-activated Vc2Vd2 T cells [16,29], we sought to
determine whether there was a connection between the increase in
IFNc-producing Vc2Vd2 T effector cells and the down-regulation
of IL-22-producing-T cells after HMBPP stimulation. To this aim,
we measured the numbers of IL-22-producing T cells and IFNc-
producing Vc2Vd2 T effector cells after HMBPP stimulation of
lymphocytes from lung, spleen and mesenteric lymph nodes in
comparison with those without HMBPP stimulation. Interestingly,
while the numbers of T cells producing IL-22 dropped signi-
ficantly after HMBPP stimulation of lymphocytes, with mean
reduced folds being 2.5760.39 in lungs (p=0.0316), 3.2560.71 in
spleens (p=0.0331) and 1.7860.14 in mesenteric lymph nodes
(p=0.0126), the numbers of IFNc-producing Vc2Vd2 T cells
increased dramatically in all these HMBPP-stimulated lymphocyte
populations (Fig. 4A, 4B and 4C). The increase in numbers of
IFNc-producing Vc2Vd2 T effector cells was most significant in
spleen lymphocytes (29.8368.71-fold increase, p,0.0001) when
compared with the numbers without HMBPP stimulation
(Fig. 4C). Two- to ten-fold increases in IFNc-producing Vc2Vd2
T cells were also seen after HMBPP-stimulation of lymphocytes
from lungs (2.2360.35, p=0.0217) and lymph nodes (9.1763.55,
p=0.0311) (Fig. 4C). We also measured production of cytotoxic
molecule perforin after HMBPP stimulation to examine if
cytotoxic effector of Vc2Vd2 T cells contributed to the down-
regulation of IL-22-producing T cells. No significant changes in
numbers of perforin-producing Vc2Vd2 T cells from blood and
BAL fluid were seen after HMBPP stimulation (data not shown).
These data provided evidence demonstrating inverse relationship
between IFNc-producing Vc2Vd2 T effector cells and IL-22-
producing T cells, suggesting that effector function of Vc2Vd2T
cells after HMBPP stimulation contributed to the down-regulation
of the capability of T cells to actively produce IL-22 de novo.
Anti-IFNc neutralizing Ab treatment reversed the
HMBPP-mediated down-regulation effect on
IL-22-producing T cells
Given the possibility that effector function of Vc2Vd2 T cells
after HMBPP activation contributed to the down-regulation effect
on IL-22-producing T cells, the central question now was whether
IFNc networking function or cytotoxic activity of Vc2Vd2 T cells
mediated the down-regulation of IL-22-producing T cells. Since
HMBPP-activated Vc2Vd2 T cells from mycobacterium-infected
macaques do not exhibit cytotoxic activity against autologous CD4
T cells [30] (data not shown), we focused on the mechanistic
studies determining whether blocking the effector function of IFNc
production by Vc2Vd2 T cells could reverse the down-regulation
Immunology of IL-22-Producing T cells in TB
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cytokine neutralization experiments using anti-IFNc neutralizing
antibody [30], and examined if neutralization of IFNc could
abrogate HMBPP-mediated down-regulation of IL-22-producing
T cells. Interestingly, anti-IFNc neutralizing antibody effectively
reversed the HMBPP-mediated down-regulation of IL-22-produc-
ing T cells (Fig. 5A, 5B). In fact, the blocking effect exerted by anti-
IFNc neutralizing antibody was so dramatic that the numbers of T
cells capable of producing IL-22 in the lymphocytes after the
HMBPP + anti-IFNc Ab co-treatment were comparable to those
seen without HMBPP stimulation in lymphocytes from lungs,
spleens, and mesenteric lymph nodes (Fig. 5A, 5B). In contrast,
Figure 2. IL-22-producing T cells were detected in situ in lung TB granulomas from M. tuberculosis infected monkeys. (A)
Representative confocal microscopic images (636numerical aperture) at the middle and bottom panels show CD3+IL-22+ T cells (marked by yellow
arrows) in lung tissue sections prepared from the right middle lung lobes at 8 weeks after M. tuberculosis infection in rhesus monkeys. The images at
the top panel show that no IL-22 (white arrows) was detectable in CD3 T cells in the peri-bronchiolar lymphoid lung section derived from healthy
macaques that received BCG vaccination 4 years before. Bar: 5 um. (B) Confocal imaging analyses show percentage numbers of IL-22-producing T
cells in the CD3+ T cells in right middle and caudal lung lobe tissues from infected rhesus macaques and undetectable numbers of these cells in lung
sections from healthy BCG-vaccinated macaques. Shown are mean percentage numbers in CD3+ T cells calculated from three M. tuberculosis-infected
macaques and three healthy BCG vaccinated controls (see Methods). IL-22-producing T cells and IL-22 negative CD3+ T cells were counted from at
least 20 confocal-section images in each of six different tissue sections from each macaque; the data from three macaques were then calculated for
means, SEM, and p values. No IL-22 staining with very low background-level fluorescence was observed when using control isotype IgG and the
antibody non-reactive with tissue-sectioning IL-22 (Data not shown). (C) Representative single-color immunohistochemistry imaging (x400) shows
that IL-22-producing T cells (brown) were distributed in granuloma from the right caudle lung lobe (infection site) of one infected rhesus macaque
(animal RH 7734, right). Similar staining data were seen in the lung sections from other M. tuberculosis-infected macaques. No IL-22-producing T cells
were detectable in lung tissues from healthy BCG vaccinated rhesus macaques (representative animal RH 27097, left). RH (Chinese rhesus macaque).
doi:10.1371/journal.ppat.1000789.g002
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PLoS Pathogens | www.plospathogens.org 5 February 2010 | Volume 6 | Issue 2 | e1000789Figure 3. Phosphoantigen HMBPP activation of Vc2Vd2 T cells down-regulated the capability of T cells to actively produce IL-22 but
not IL-17 de novo in lymphocytes from blood, lungs/BAL fluid, spleens and lymph nodes. Cells from different compartments were either
un-stimulated (CD28/CD49d) or stimulated with HMBPP (HMBPP plus CD28/CD49d), and then subjected to intracellular cytokine staining. Blood and
BALF were taken at the endpoint matching necropsy schedule after M. tuberculosis infection. (A) Shown on the top panel are representative flow-
cytometry histograms of intracellular cytokine staining analysis. The percentage numbers of IL-22-producing T cells in lymphocytes are marked above
individual histograms. The bottom-panel flow-cytometry histograms show that HMBPP activation resulted in a reduction in numbers of T cells
capable of producing IL-22. The numbers in parentheses denote folds of reduction (ratio of numbers of IL-22-producing T cells from unstimulated
versus HMBPP stimulated measurements) after HMBPP treatment. Data were gated on CD3. The flow histograms were from representative M.
tuberculosis-infected macaque CN7234 (blood), CN7222 (BAL fluid), RH7716 (lung), RH7717 (spleen) and RH7720 (mesenteric LN) respectively. CN
(cynomolgus macaque). (B) Comparative analyses of IL-22-producing T cells in the presence and absence of HMBPP stimulation. Data are mean
percentage numbers 6 SEM derived from macaque animals’ blood (n=7, cynomolgus), BAL fluids (n=5, cynomolgus), lungs (n=7, rhesus), spleens
(n=11, rhesus) and mesenteric lymph nodes (n=8, rhesus). *, P,0.05, **, P,0.01. Data were gated on CD3. (C) Bar graphic data show percentages
(left) and folds (right) of down-regulation of IL-22-producing T cells after HMBPP stimulation. The fold of down-regulation was defined the same as
above in Fig. 3A. The percentages of down-regulation were calculated by the formula [(Unstimulated–HMBPP-stimulated)/Unstimulated 6100%].
Results were shown as mean 6 SEM. Data were gated on CD3. (D) Comparative analyses of IL-17-producing T cells in the presence and absence of
HMBPP stimulation. Data are mean percentage numbers 6 SEM derived from macaque animals’ blood (n=9, cynomolgus), BAL fluids (n=9,
cynomolgus), lungs (n=15, rhesus), spleens (n=16, rhesus) and mesenteric lymph nodes (n=20, rhesus). Data were gated on CD3.
doi:10.1371/journal.ppat.1000789.g003
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PLoS Pathogens | www.plospathogens.org 6 February 2010 | Volume 6 | Issue 2 | e1000789Figure 4. Up-regulation of IFNc-producing Vc2Vd2 T effector cells after HMBPP stimulation coincided with the down-regulated
capacity of T cells to produce IL-22 de novo. (A) Representative paired flow-cytometry histograms from monkey RH7406 (lung), RH7720 (spleen),
RH7357 (mesenteric lymph node) show intracellular cytokine staining data indicating that HMBPP stimulation up-regulated numbers of CD3+
IFNc+Vc2+ T cells (right) and down-regulated numbers of CD3+IL-22+ T cells (left) in lymphocytes from lungs, spleens and mesenteric lymph nodes
(LN). Cells were gated on CD3. Percentage numbers of IL-22+ or IFNc+Vc2+ T cells in CD3 T cells are listed above individual histograms, and folds of
up-regulation (the ratio of HMBPP-stimulated versus unstimulated) or down-regulation are indicated in parentheses. Note that 1 hour HMBPP
stimulation did not increase the number of entire Vc2Vd2+ T cells (including both IFNc+ and IFNc-V c2Vd2+ T-cell populations) in CD3+; the
percentage of Vc2Vd2+ T cells in CD3+ remained similar in the presence or absence of HMBPP (HMBPP enabled some IFNc-V c2Vd2+ T cells to
become IFNc+ Vc2Vd2+ T cells). The decreased numbers of IL-22-producing T cells were not due to expansion of Vc2Vd2+ T cells after 1-hr HMBPP
activation. (B) Comparative analyses of flow-cytometry data indicating that HMBPP stimulation up-regulated percentage numbers of IFNc+Vc2+ T
cells (top panels) and down-regulated percentage numbers of IL-22+ CD3+ T cells (bottom) in lymphocytes from lungs (n=6), spleens (n=8) and
mesenteric lymph nodes (n=5). Data were means 6 SEM derived from eight infected rhesus macaques and were gated on CD3. *, P,0.05, ***,
P,0.001. (C) Comparative data indicating mean folds of up-regulation of CD3+IFNc+Vc2+ T cells (top) and down-regulation of CD3+IL-22+ T cells in
lymphocytes from lungs (n=6), spleens (n=8) and mesenteric lymph nodes (n=5). Data were derived from eight infected rhesus macaques and were
gated on CD3.
doi:10.1371/journal.ppat.1000789.g004
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producing T cells (Fig. 5A, 5B). These results suggested that cd T-
cell-driven IFNc-networking function was one of the mechanisms
by which phosphoantigen-activated Vc2Vd2 T effector cells
down-regulated the capability of T cells to produce IL-22 de novo
during M. tuberculosis infection.
Discussion
The current study represents the first extensive investigation of
the development, distribution, and immune regulation of IL-22-
producing T cells differentiated from primary M. tuberculosis
infection. Interestingly, tuberculosis-driven T cells can actively
Figure 5. Anti-IFNc neutralizing Ab treatment reversed the HMBPP-mediated down-regulation effect on IL-22-producing T cells.
Cells from different anatomic compartments were either un-stimulated or stimulated with HMBPP, HMBPP + anti-IFNc neutralizing Ab, or HMBPP +
isotype matched IgG Ab, and then subjected to intracellular cytokine staining. (A) Representative flow-cytometry histograms from monkey RH7717
(lung), RH7719 (spleen) and RH7720 (mesenteric lymph node) show intracellular cytokine staining data demonstrating that anti-IFNc neutralizing Ab
but not isotype IgG reversed the HMBPP-mediated down-regulation of IL-22+CD3+ T cells in lymphocytes from lungs, spleens and mesenteric lymph
nodes (LN). Cells were gated on CD3. Percentage numbers of CD3 T cells are listed above individual histograms. (B) Comparative flow-cytometry data
show that anti-IFNc Ab but not isotype IgG reversed the HMBPP-mediated down-regulation of IL-22+CD3+ T cells in lymphocytes from lungs, spleens
and mesenteric lymph nodes (LN). Data were mean 6 SEM derived from rhesus macaque animals’ lungs (n=7), spleens (n=9) and mesenteric lymph
nodes (n=14). *, P,0.05, **, P,0.01. Addition of exogenous IFNc to PBMC culture was not able to activate/expand Vc2Vd2 T cells or to down-
regulate mature IL-22-producing T cells (data not shown).
doi:10.1371/journal.ppat.1000789.g005
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antigen re-stimulation. The increase in numbers of IL-22 or IL-17
producing effector T cells is particularly evident in the lung tissues
during the late stage of M. tuberculosis infection. More importantly,
in situ studies using confocal microscopy and immunohistochem-
istry can readily detect these IL-22-producing T cells in lung tissue
sections and granulomas (Fig. 2A, 2B, and 2C) from infected
monkeys, indicating that IL-22-producing T cells are present in
TB granulomas or lesions. These findings are quite contrasted to
the recent report showing that Th17 cells in M. tuberculosis-infected
individuals are detected under the condition of in vitro antigen re-
stimulation [15]. It is generally believed that cytokine proteins
produced by CD4 T cells usually can not be detected directly in
vivo unless they receive potent in vitro Ag re-stimulation. The
presence of large numbers of IL-22-producing T cells in lungs
suggests that M. tuberculosis antigens may have activated these cells
to a great extent so that they are capable to produce large quantity
of IL-22 or IL-17 in vivo. This notion is consistent with greater
numbers of IL-22- or IL-17-producing T cells distributed in lung
tissues with high TB burden and severe TB lesions. These T cells
appear to be fully matured or differentiated after exposure to M.
tuberculosis,a sin vitro stimulation by triggering TCR/CD3 signaling
using anti-CD3/CD28 do not dramatically increase or decrease
the number of IL-22-producing T cells in lymphocytes (Fig. 1B,
and data not shown).
It is noteworthy that human IL-22-producing Th17 cells
detected at cross-sectional time points in patients with active TB
are lower than those in healthy mycobacterium-exposed individ-
uals [15]. The explanation for this may be simply due to the
difference in immune competence between chronically-active
adult tuberculosis in humans and primary M. tuberculosis infection
in macaques. Chronically active adult TB usually occurs as a result
of reactivation TB somehow after immune control of primary M.
tuberculosis infection, and often display depressed cellular immune
response [34,35]. Therefore it is not surprised that the levels of IL-
22 and IL-17 producing Th17 cells in active TB patients are lower
than those in M. tuberculosis-exposed healthy controls. Tuberculo-
sis-driven IL-10-producing T cells might down-regulate human
IL-22 and IL-17 producing Th17 cells in chronically-active TB
[36]. In contrast, the macaques in our studies were naı ¨ve at the
time of experimental M. tuberculosis infection, and were able to
develop competent immune responses, characterized by the
increased numbers of IFNc+ and TNFa+ Th1 cells in the blood
and lungs following M. tuberculosis infection (data not shown).
Furthermore, IL-10-producing T cells in this study are almost
undetectable or extremely low during primary M. tuberculosis
infection (data not shown). Therefore, these differences may help
to explain why we see apparent increases in IL-22-producing T
cells during primary M. tuberculosis infection of naı ¨ve macaques,
whereas chronically-active TB patients display depressed responses
of IL-22-producing T cells.
Our study provided the first evidence that T cells actively
producing IL-22 are susceptible to down-regulation by immune
activation of certain T effector subsets. We have shown that the
capability of T cells to produce IL-22 can be down-regulated by
phosphoantigen activation of Vc2Vd2 T effector cells. Such
relationship between IL-22-producing T cells and HMBPP
activation of Vc2Vd2 T effector cells may somehow predict the
in vivo cell-cell interaction in lung and lymphoid tissues. In fact,
these two different T effector cell subpopulations co-exist in all
anatomic compartments tested during M. tuberculosis infection
(Figs. 3–5). Particularly, these two T cell subpopulations
producing their own effector cytokines can be detected in situ in
M. tuberculosis infected lung tissues and TBg r a n u l o m a s( F i g .2 A ,
2C, [31]). The negative effects of Vc2Vd2 T effector cells on
IL-22-producing T cells underscores broad regulatory func-
tion of Vc2Vd2 T effector cells as phosphoantigen-activation
of Vc2Vd2 T cells can also antagonize IL-2-induced
CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infec-
tion [30]. On the contrary, HMBPP activation of Vc2Vd2Tc e l l s
did not significantly down-regulate IL-17-producing T cells.
While the mechanism for the selective down-regulation of IL-22-
producing T cells is unknown, it is possible that IL-22-producing
T cells and IL-17-producing T cells are two distinct T cell subsets
in macaques, and therefore regulated by different mechanisms
[15]. This is consistent with the report describing distinct IL-22
and IL-17 producing Th17 cells among CD4 T cells in active
pulmonary TB patients [15]. It was noteworthy that in order to
perform consistent or comparable evaluation of T effector cells in
different compartments in TB, we collected blood and BALF
(Fig. 3) at the end point matching the necropsy schedule to study
the interaction between Vc2Vd2 T cells and IL-22/IL-17-
producing T cells. The frequency of IL-22-producing T cells at
the end stage might be highest (Fig. 1A) in all different
compartments so that cd T-cell-driven down-regulation of IL-
22-producing T cells was quite evident.
Our mechanistic study in IFNc-neutralizing experiments
demonstrate that IFNc networking function from HMBPP-
activated Vc2Vd2 T effector cells can effectively down-regulate
the IL-22 production effector function of IL-22-producing T cells
that are matured or differentiated during M. tuberculosis infection.
Molecular pathways for IFNc networking function from Vc2Vd2
T-cells in down-regulation of IL-22 producing T cells may be
complex, since exogenous IFNc is not able to activate/expand
Vc2Vd2 T cells or to down-regulate mature IL-22-producing T
cells (data not shown). We cannot exclude the possibility that
endogenous IFNc acts in concert with other cytokines produced
by Vc2Vd2 T effectors to down-regulate IL-22-producing T
cells. The current finding suggests that IFNc networking function
from HMBPP-activated Vc2Vd2Tc e l l ss e r v e sa tl e a s ta sa
negative host factor for down-regulation of IL-22 producing T
cells during M. tuberculosis infection. The cd T-cell-driven IFNc
networking function may be significant for the potential in vivo
regulation of IL-22-producing T cells by Vc2Vd2 T effector cells.
HMBPP produced by M. tuberculosis metabolite pathway can
activate Vc2Vd2 T cells with endogenous production of IFNc
and other effectors, leading to down-regulation of IL-22-
producing T cells.
Given the possibility that IL-22-producing T cells may be
either inflammatory/pathogenic or protective during infections
depending upon bacterial burdens and host conditions, HMBPP-
activated Vc2Vd2 T effector cells may play a regulatory role in
balancing IL-22-mediated inflammatory and anti-microbial
responses. During a M. tuberculosis infection with low-level
bacterial burdens, activation extent of Vc2Vd2Tc e l l sa n dI L -
22-producing T cells would be low or limited due to low-level
production of HMBPP and protein Ags. Such low-degree
activation of Vc2Vd2 T cells would lead to no or subtle down-
regulation of IL-22 production. Thus, low or moderate levels of
IL-22 may facilitate potential innate responses by promoting
pulmonary epithelial cells’ capacity to produce antimicrobial
peptides [3,6,7,37]. On the other hand, high bacterial burdens
during severe M. tuberculosis infection may induce unbalanced
overproduction of IL-22 and severe lesions [14], an outcome
consistent with IL-22-mediated inflammatory responses and
diseases [8,9,37]. In this case, potent activation of Vc2Vd2T
cells driven by high-level production of HMBPP in severe
tuberculosis may potentially down-regulate IL-22-production
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From this standpoint, the findings from the current work raise the
possibility to determine whether the HMBPP treatment regimen
for expanding Vc2Vd2 T effector cells [29] may confer some
therapeutic benefits regulating tuberculosis lesions.
Thus, we have demonstrated differentiation, local/systemic
distribution and immune regulation of mature T cells capable of
producing IL-22 de novo during M. tuberculosis infection. Particu-
larly, we have illustrated that phosphoantigen activation of
Vc2Vd2 T cells can down-regulate IL-22-producing T cells
through IFNc-networking function. Since the role of IL-22-
producing T cells in M. tuberculosis infection remains unknown in
humans, our current findings provide a useful system to further
understand the interplay between IL-22-producing T cells and
Vc2Vd2 T effector cells in M. tuberculosis infection and their
mutual contribution to anti-tuberculosis responses.
Materials and Methods
Ethics statement
The use of macaques and experimental procedures were
approved by Institutional Animal Care and Use Committee and
Biosafety Committee, University of Illinois College of Medicine at
Chicago (UIC), and we followed the national and international
guidelines regarding ‘‘The use of non-human primates in research
to minimize potential suffering of the studied macaques. Daily or
weekly clinical follow-up were taken to ensure that animals were
not suffering from severe coughing, respiratory distress, depres-
sion, refusion to take food, body-weight loss or other potential life-
threatening signs. Human euthanization procedures were imme-
diately taken if those signs occur progressively.
Animals
Fifteen adult cynomolgus macaques ranging in age from 3 to 9
years old and eighteen adult Chinese rhesus macaques monkeys
ranging in age from 4 to 11 years old were used in this study.
Cynomolgus and rhesus macaques exhibited similar responses of
IL-22-producing T cells and Vc2Vd2 T cells after M. tuberculosis
infection. All monkeys were naı ¨ve prior to M. tuberculosis infection,
based on tuberculin skin tests, IFNc ELISOPOT assays, and
thoracic radiographs. M. tuberculosis infected macaques were
housed at the Biologic Research Resources Annex BSL3
nonhuman primate facilities in UIC and sacrificed at 8 weeks
after infection. As a control, tissues sections for in situ IL-22
detection were prepared from lung tissues of 3 healthy rhesus
monkeys, which were vaccinated intravenously with 10
6 CFU
BCG Pasteur 4 years earlier (Fig. 2). As another control, BAL fluid
was collected from nine naı ¨ve cynomolgus macaques to measure
IL-17- or IL-22-producing T cells (Fig. 1A).
M. tuberculosis infection
Each monkey was infected with 500 CFU of M. tuberculosis
Erdman (the standard challenge stock from FDA) by the
bronchoscope-guided injection of the inoculum into the right
caudal lobe as previously described [31,32]. This was done in the
procedure room at the Annex BSL3 nonhuman primate facilities
at UIC. The inoculum used for infection was diluted and plated on
7H11 agar plates (BD) to further confirm the bacterial CFU dose
for inoculation.
Bronchoalveolar lavage (BAL)
This was done essentially the same as previously described
[29,31].
Isolation of lymphocytes from blood, BAL fluid, lung,
spleen and mesenteric lymph nodes
PBMC were isolated from freshly collected EDTA blood by
Ficoll-Paque
plus (Amersham, Piscataway, NJ) density gradient
centrifugation. For isolation of lymphocytes from BAL fluid,
freshly retrieved BAL fluid was filtered through 40-um cell
strainers (BD) into 50 ml-conical tubes (BD) followed by 5 min
61500 rpm centrifugation. The supernatant was gently discarded
without disturbing the cell pellets. Cell pellets were then treated
with 5 ml RBC blood lysis buffer (Sigma-Aldrich) for 10 min or
waited till the suspension became clear and washed once with 5%
FBS-PBS. Lung and spleen tissues were minced with sharp scissors
and squeezed with sterile copper mesh in Petri dish and colleted
with RPMI followed by filtering through 40-um cell strainers.
Mesenteric lymph nodes were carefully teased apart with 18-gauge
needle in Petri dish with RPMI to form single cell suspension.
Collected cell suspensions from lung, spleen and mesenteric lymph
nodes were further purified by Ficoll-Paque
plus density gradient
centrifugation to collect pure lymphocytes. The freshly isolated
lymphocytes from blood, BAL fluid, lung, spleen and mesenteric
lymph nodes were stained by trypan blue to identify the viability
and numerate cell counts. The lymphocytes were finally suspended
into 10% FCS-RPMI media with a concentration of 10
7 cells/ml
for further study.
Antigens (Ag) and Antibodies (Ab)
Phosphoantigen compound HMBPP was produced, character-
ized, validated and provided by Dr. Hassan Jomaa from Justus-
Liebig-Universita ¨t Giessen, Giessen, Germany. HMBPP used in
the study was .98% pure [29], and specifically stimulated
activation/expansion of Vc2Vd2 T cells but not other cell
subpopulations[28]. This allowed us to determine if HMBPP
activation of Vc2Vd2 T cells in lymphocytes could down-regulate
IL-22-producing T cells in the CD3+ T-cell pool. PPD and 15mer
overlapping peptides spanning Ag85B were purchased from
Mycos Research (Loveland, CO) and GenScript Corporation
(NJ), respectively. Anti-CD28 (CD28.2, BD) and anti CD49d
(9F10, BD) were used in the assays as costimulatory Abs. The
following Abs were used for surface and intracellular cytokine
staining for flow cytometry: CD3-PECY7 (SP34-2, BD), CD4-
FITC (L200, BD), Vc2-FITC (7A5, Endogen), IFNc-Allophyco-
cyanin (4S.B3, BD), IL-17-PE (eBio64CAP17, eBioscience), IL-22-
biotinylated (anti-human, RD), streptavidin-Pacific blue (invitro-
gen). Anti-IFNc neutralizing Ab (MD-1, eBioscience) and purified
mouse IgG isotype control (eBioscience) were used in blocking
assay.
Intracellular cytokine staining (ICS) assays, anti-IFNc
neutralizing Ab blocking assay, and control experiments
10
6 lymphocytes isolated from blood, 10
6 or 3–5610
5
lymphocytes (depending on availability) from BAL fluid, lung,
spleen and mesenteric lymph node were used in each reaction
(round bottom 96-well plate) to measure IL-22- or IL-17-
producing T cells as well as IFNc- or perforin-producing Vc2Vd2
T cells. Lymphocytes were incubated for one hr with (i) medium
alone (termed No CD28/CD49d), (ii) medium plus co-stimulatory
CD28 (1 ug/ml) and CD49d (1 ug/ml) mAbs (termed CD28/
CD49d), or (iii) HMBPP (40 ng/ml) plus CD28/CD49d mAbs
(termed HMBPP). For confirmation purposes, lymphocytes were
also incubated for one hr with medium plus CD3 (1 ug/ml)
and CD28 (1 ug/ml) mAbs (termed CD3/CD28), PPD (20 ug/ml)
plus CD28/CD49d mAbs, or 15mer overlapping peptides
spanning Ag85B (2 ug for each peptide) plus CD28/CD49d
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final volume in round bottom 96-well plates at 37uC, 5% CO2,
followed by five hr incubation in the presence of brefeldin A
(GolgiPlug, BD). We found that at late time points after M.
tuberculosis infection, appreciable numbers of IL-22-producing T
cells could be directly measured by the intracellular cytokine
staining (ICS) without in vitro antigen stimulation, and that
numbers of IL-22-producing T cells directly measured in medium
only were comparable with those detected in medium plus CD28/
CD49d mAbs or medium plus CD3/CD28 mAbs (Fig. 1B, and
data not shown).
For anti-IFNc neutralizing antibody blocking assay, 10
6 or 3–
5610
5 lymphocytes from lung, spleen and mesenteric lymph node
were treated as a test group with anti-IFNc neutralizing Ab (5 ug/
ml) together with HMBPP (40 ng/ml) in presence of CD28/
CD49d mAbs. As control groups, cells were treated with medium
plus CD28/CD49d mAbs only, HMBPP plus CD28/CD49d
mAbs, or HMBPP plus mouse isotype IgG (5 ug/ml) and CD28/
CD49d mAbs. The 1 hr reaction was followed by 5 h incubation
with brefeldin A as described above.
After a total of six hr incubation, cells in 96-well plate were
transferred into 5 ml polystyrene round bottom tubes (BD) for
surface and intracellular staining. Cells were washed once with 2%
FBS-PBS and stained at RT for at least 15 min with surface
marker Abs (CD3, CD4 and Vc2) followed by twice wash with 2%
FBS-PBS. Cells were permeabilized for 45 min (cytofix/cytoperm,
BD) and washed twice by Perm buffer (BD), and then stained
another 45 min for IFNc, IL-17 and IL-22-biotinylated and
repeated Perm wash twice. Cells stained with biotinylated-IL-22
were further stained for 45 min with streptavidin-pacific blue
conjugate followed by final twice Perm buffer wash. Last, cells
were resuspended in 2% formaldehyde-PBS (Protocol Formalin,
Kalamazoo, MI) and subjected to flow cytometry analysis.
To ensure the specific immune staining in ICS, matched normal
serum or isotype IgG served as negative controls for staining
cytokines or surface markers. As in vivo control experiments,
PBMC were obtained biweekly for 8 weeks from three healthy
uninfected and five SHIV-infected cynomolgus macaques, and
assessed for IL-22-producing T cells using the ICS assay as
described above (medium only or medium plus CD28/CD49d).
No or very few IL-22-producing T cells (,0.02% of CD3) were
detectable in the longitudinal control experiments (data not
shown).
Flow cytometry analysis
Fixed lymphocytes were run on a CyAn ADP flow cytometer
(DakoCytomation, Carpinteria, CA) for analysis. Lymphocytes
were gated based on their forward scatter, side scatter and pulse-
width characteristics. At least 40,000 gated events were analyzed
using Summit Data Acquisition and Analysis Software created by
DakoCytomation. Cells stained with different color conjugated
Abs alone were used as controls and to estimate the amount of
compensation needed for the different color combinations. Further
gating and determination of quadrant position for analysis were
based on specific Ab staining (positives) together with negative
background determined by either unstained cells or isotype control
stained cells. Flow cytometric dot plots were displayed by bi-
exponential scaling. Since IL-22-producing T cells and Vc2Vd2T
cells both expressed CD3, flow-cytometry gating on CD3
objectively revealed HMBPP-stimulated increases in percentages
of IFNc-producing Vc2Vd2 T cells and associated decreases in
percentages of IL-22-producing T cells within the CD3+ T-cell
population. Such interrelation between Vc2Vd2 T cells and IL-
22-producing T cells could not be precisely determined by
presenting IL-22-producing cells in CD4+ T cells because
Vc2Vd2 T cells usually do not express CD4. Furthermore,
because IL-22 was also produced by CD8 T cells and cd T cells
(Fig. S1), determining IL-22 production in CD3+ T cells would be
more conclusive than in CD4+ T cells.
Confocal microscopy imaging
<5-mm-thick frozen lung sections were prepared, as we recently
described [31], from optimal cutting temperature compound
(OCT)-embedded lung tissues from healthy macaques vaccinated
with BCG four year before, or M. tuberculosis-infected macaques.
Tissue sections were first incubated overnight in a wet box with
polyclonal rabbit anti-human IL-22 (N-terminus, Capralogics,)
and monoclonal mouse anti-human CD3 (F7.2.38, Dako) or
isotype control IgG or normal rabbit serum. After thoroughly
washed with PBS, tissue sections were fixed with 2% formalin and
washed thoroughly with PBS. Tissue sections were then incubated
with FITC-conjugated donkey anti-rabbit IgG (Biolegend) and
Cy3-conjugated goat anti-mouse IgG (Biolegend, USA), followed
by thorough PBS washing. Next, tissue sections were fixed gently
with 2% formalin again and washed thoroughly with dd water to
remove the salt in PBS. Finally, tissue sections were mounted on
slides using fluorescence mounting medium with DAPI for
confocal microscope [Zeiss, LSM 510, (636numerical aperture)]
imaging.
Immunohistochemistry analysis of IL-22 producing T cells
in lung tissues
Standard protocols for immunohistochemical analyses were
used to evaluate IL-22-producing T cells in lung tissue sections
prepared from OCT-embedded tissues as we previously described
[31]. A peroxidase-based visualization kit (Envision system K1395;
Dako, Caprinteria, CA) was used for immunohistochemical
staining. Frozen specimens embedded in OCT were cut into 6-
um thick sections by use of a cryostat, fixed, permeabilized in cold
acetone for 10 min, and washed in PBS. The sections were treated
for 10 min with 1% hydrogen peroxide in PBS to quench
endogenous peroxidase, rinsed in PBS, blocked for 10 min with
serum-free protein block (X0909; Dako), and rinsed in PBS. The
sections were incubated with rabbit anti-human IL-22 (CI0144;
Capralogics) Ab at a concentration of 50 ug/ML for 1 h at room
temperature and then incubated for 30 min with peroxidase-
labeled polymer-conjugated goat anti-rabbit immunoglobulin.
The sections were rinsed in PBS after each incubation, developed
using 3,39-diaminobenzidine chromogen solution as a substrate for
3–6 min, and counterstained with Gill’s hematoxylin (Fisher
Scientific) for 2 seconds. After dehydration in grade alcohols,
sections were cleared in xylene and coverslipped.
Statistical analysis
Statistical analysis was done by using GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA). Normality test was first
performed to decide whether the data were normally distributed.
All the data in this study passed the normality test, and analyzed
by Student t test (parametric method). All the P values shown in
this study were derived from Student t test. P,0.05 was
considered significant. Only P values ,0.05 were shown in the
text.
Supporting Information
Figure S1 T cells producing IL-22 are mainly produced by
CD4+ T cells during M. tuberculosis infection. Bar graphic data
show the percentages of CD4, CD8 and Vc2Vd2 T cells among
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(n=4, rhesus) at necropsy. Data were mean6SEM and gated on
CD3.
Found at: doi:10.1371/journal.ppat.1000789.s001 (0.02 MB
DOC)
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